198 Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine co... by Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Benjamin Cuiffo, Andrej Jedinak

474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to miti... by Melissa Maxwell, Dingxue Yan, James Cardia, Benjamin Cuiffo, Brianna Rivest, Andrew Boone

599 New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma by Elfriede Noessner, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Anna Herbstritt, Petra Prinz, Mani Kadiyala

172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM) by Andrew Weinberg, Ryan Montler, Colin Thalhofer, Tarsem Moudgil, Bernard Fox, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Nick Morris, B Bell

Self-delivering RNAi compounds as therapeutic agents in the central nervous system to enhance axonal regeneration after injury by Sarah A. Woller, Joerg Ruschel, Barbara Morquette, James Cardia, Dinxue Yan, Katherine Holton, Taisia Shmushkovich, Emily Niederst, Karen Bulock, Alexey Wolfson, Matthew Abbinanti, Alyson E. Fournier, Lisa McKerracher, Kenneth M. Rosen

Get full text